- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Skye Bioscience Inc (SKYE)
Skye Bioscience Inc stock price live, this page displays NASDAQ SKYE stock exchange data. View the SKYE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Skye Bioscience Inc real time stock price chart below.
What Is the Skye Bioscience Inc Stock Price Today?
The Skye Bioscience Inc stock price today is 3.6300.
What Is the Stock Symbol for Skye Bioscience Inc?
The stock symbol for Skye Bioscience Inc is ""SKYE.""
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SKYE quote. (ISIN: US83086J2006)
What Is the Skye Bioscience Inc Stock Price Today?
The Skye Bioscience Inc stock price today is 3.6300.
What Is the Stock Symbol for Skye Bioscience Inc?
The stock symbol for Skye Bioscience Inc is ""SKYE.""
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SKYE quote. (ISIN: US83086J2006)
NASDAQ
Currency in USD
3.6300
0.0000(0.00%)
Closed·
Fair Value
An estimate of a Skye Bioscience's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.4175
3.7050
52 wk Range
1.1400
7.4700
SKYE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SKYE is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Skye Bioscience's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.41753.7050
52 wk Range
1.14007.4700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SKYE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Skye Bioscience's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
15.5000
Upside
+327.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Skye Bioscience Inc Company Profile
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Skye Bioscience Inc SWOT Analysis
Nimacimab's Promise | Skye Bioscience's lead candidate for obesity treatment shows potential for efficacy without neuropsychiatric side effects, addressing a critical market need |
Financial Runway | With $59.2 million in cash, Skye is funded through Q1 2027, providing ample time for key clinical milestones and potential strategic developments |
Market Opportunity | Explore how Skye's novel approach to obesity treatment could capture a significant share of a growing market, potentially attracting big pharma interest |
Analyst Optimism | Learn about the bullish outlook from analysts, with price targets ranging from $14 to $15, reflecting confidence in Skye's innovative obesity treatment approach |
Skye Bioscience Inc Earnings Call Summary for Q1/2025
- R&D expenses rose to $7.2M in Q1 2025, up from $1.9M in Q1 2024; cash reserves at $59.2M, funding operations through Q1 2027
- Completed enrollment in Phase IIa CBEYOND trial; targeting obesity treatment market with Nimazumab therapy
- Net loss of $11.1M for Q1 2025; stock unchanged at $2.55, reflecting stable investor sentiment
- Expects top-line weight loss data in late Q3/early Q4; plans to initiate Phase 2b monotherapy dose-ranging study
- CEO highlights robust CB1 inhibition; CSO expresses confidence in drug's clinical potential
Last Updated: 08/05/2025, 22:40
Read Full TranscriptCompare SKYE to Peers and Sector
Metrics to compare | SKYE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSKYEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.3x | −0.5x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 10.2x | 3.3x | |
Upside (Analyst Target) | 283.6% | 189.3% | 43.5% | |
Fair Value Upside | Unlock | 1.7% | 6.3% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 15.5000
(+327.00% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.28 / -0.21
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Skye Bioscience Trade On?
Skye Bioscience is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Skye Bioscience?
The stock symbol for Skye Bioscience is "SKYE."
What Is the Skye Bioscience Market Cap?
As of today, Skye Bioscience market cap is 101.87M.
What Is Skye Bioscience's Earnings Per Share (TTM)?
The Skye Bioscience EPS (TTM) is -0.83.
From a Technical Analysis Perspective, Is SKYE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Skye Bioscience Stock Split?
Skye Bioscience has split 2 times.
How Many Employees Does Skye Bioscience Have?
Skye Bioscience has 16 employees.
What is the current trading status of Skye Bioscience (SKYE)?
As of 05 Aug 2025, Skye Bioscience (SKYE) is trading at a price of 3.63, with a previous close of 2.55. The stock has fluctuated within a day range of 3.42 to 3.71, while its 52-week range spans from 1.14 to 7.47.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.